Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of JPI-547 in Healthy Korean, Caucasian and Chinese Participants
NCT07570186Phase 1Not yet recruiting
- Sponsor
- Onconic Therapeutics Inc.
- Start
- May 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nesuparib in cancer (2 arms), sponsored by Onconic Therapeutics Inc. Primary endpoints: Maximum Plasma Concentration of JPI-547, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration of JPI-547 and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
nesuparib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07570186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570186.